Shire PLC (LSE:SHP) - Share price - Overview

Stock Report

Shire PLC SHP

Last Price
GBX4,520.00

Day Change
9.00|0.20%

As of 27/06/2017
17:05:35 BST | GBX
Minimum 15 Minutes Delay.

Last Close4,511.00p
Day Range4,517.15 - 4,556.00
Mkt Cap40.92Bil
52-Wk Range2,707.19 - 5,377.00
Yield %0.42
ISINJE00B2QKY057
Volume575,857
P/E28.06
P/S4.12
P/CF17.67

Share Price

Total Returns 27/06/2017

 Chg (%)  
More ...
Shire PLC-2.85 
FTSE 100 TR GBP-1.21
 
Financials
201420152016
More ...
Income Statement
Turnover3,664.344,199.928,442.60
Operating Profit1,033.20929.11713.32
Net Profit1,995.88876.87453.52
Reported EPS337.83147.9257.04
Balance Sheet
Current Assets3,330.061,530.296,101.64
Non Current Assets5,428.359,738.9648,149.44
Total Assets8,758.4011,269.2554,251.08
Current Liabilities1,941.522,514.486,266.57
Total Liabilities3,192.634,600.5030,823.75
Total Equity5,565.776,668.7523,427.33
Cash Flow
Operating Cash Flow2,572.911,529.641,969.71
Net Change in Cash457.76-1,861.42290.76
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
20172,998.64387.74140.7111.630.0831.120.69
20183,912.54436.1112.4810.340.8335.330.78

Regulatory News

DateAuthor Headline
09/11/2016Karen Kwok Healthcare and Mining Stocks Gain On Trump Win
FTSE 100: Mining, healthcare and building stocks rallied in London this morning as news of Donald Trump's US presidency crossed the pond
15/02/2016Stefan Quenneville, CFA Analysts Downgrade Shire
Morningstar equity analysts are lowering Shire's fair value estimate to account for the impact of the acquisition of Baxalta. Through several acquisitions, Shire has transformed
03/02/2016Emma Wall 3 Stocks Boosted by M&A Activity
These three UK stock picks from Henderson's James Ross have all benefitted from the tailwind of M&A activity - from the very racy to the boring and banal
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
31/03/2017PurchaseMs. Anne Minto4,742.281336,307.00
31/03/2017PurchaseMr. Bill Burns4,742.281366,450.00
31/03/2017PurchaseDr. David Ginsburg5,861.151207,033.00
31/03/2017PurchaseOlivier Bohuon4,742.281185,596.00

Company Profile

Shire PLC is a biotechnology company focused mainly in the research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Sector

Biotechnology

Market Position

15 of 1845 Companies

Index

FTSE 100 ,FTSE 350 ,S&P Europe 350 ,Eurotop 300 ,FTSE All Share

Outlook

(02/05/2017) ceo - "...we are on track to achieve our full-year financial guidance"

Next Event 02/08/2017

Next interim announcement
Ratios
CompSecMkt
More ...
PER (E)10.9715.4816.73
Div Yld (E)0.743.534.11
PEG (E)0.210.471.01
ROCE24.47190.3017.49
Op Mrgn17.79-3.152.90
EPS Grwth52.0444.4131.85
Dividends
PreviousLatest
More ...
Record Date09/09/1610/03/17
Ex-Div08/09/1609/03/17
Paid07/10/1625/04/17
Amnt3.5120.64

Broker Sentiment

Strong Buy0
Buy3
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMs. Susan Kilsby
Chief Executive OfficerDr. Flemming Ornskov
Chief Financial OfficerMr. Jeff Poulton
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.